RANDOM NEWS with updates for Letrozole

*BIG 1-98 showed that LETROZOLE was more effective in post-menopausal patient with any histology of breast cancer that is ER positive and Her-2 Negative, with the effect being greater in lobular type of Carcinoma.  And in Luminal B versus Luminal A.

* In HER-2 positive, one year Vs 2 Years.
"2 year long treatment not recommended",
finding of the HERA trial remains the standard of care.

In the study of 6 months Vs 12 months of Herceptin, there was a trend toward better results with 12 months also statistically no difference was detected.

*In Early Breast cancer, High Baseline of Vitamin D level was a predictor of 3 things:
1. better prognosis
2. low risk bone relapse
3. better outcome with use of Zometa.

recommendation is to measure Vit D at diagnosis and to replenish it!

*In triple negative breast cancer, the disease would be amenable to new type combinations of medications such as
A/  Cisplatin /PARP (olaprib) and Vandetanib (EGFR/VEGF).
B/  Cisplatin/PARP inhibitor and   Vorinostat (Histone deacetylase inhibitor)
C/  Androgen Inhibitors and MTOR

*PD 0332991, an oral Cyclin dependent Kinase (CDK 4/6) inhibitor added to Letrozole  increased the progression free from 7.5 months to 26.1 months.  This is an impressive performance if confirmed. 
 *PIM-1 may be a surrogate of c-MYC  amplification, and is being targeted.

* Routine Breast MRI still not recommended

*32mg IV Ondansetron  can cause Arrhythmia and has been withdrawn.

TALKING DE-ACETYLATION, PANOBINOSTAT

Panobinostat is a De-acetylator inhibitor for Histone, meaning that it paralyzes a few enzymes perinuclearly, therefore blocking Mitosis this way.
It has demonstrated Activity in Relapsed/Refractory Hodgkin's disease post transplantation. An area where it does not have much competition.   And here it is actually pretty good at achieving like most target therapies a 30% effectiveness and  with additional stable diseases.  A respectable effectiveness.
Now  it is being tried in Non Hodgkin's disease with Rituxan.  We will update you on this!

Targeting Triple-Negative Breast Cancer Cells With the Histone Deacetylase Inhibitor Panobinostat

Targeting Triple-Negative Breast Cancer Cells With the Histone Deacetylase Inhibitor Panobinostat Chandra R Tate, Lyndsay V Rhodes, H Chris Segar, Jennifer L Driver, F Nell Pounder Matthew E Burow, Bridgette M Collins-Burow Jul 27, 2012 Authors & Disclosures Breast Cancer Res. 2012;14(3):R79 © 2012 BioMed Central, Ltd. This article catches the Attention of the CRBCM. Thank you Medscape Alert!